Literature DB >> 8481661

Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.

E H Estey1, W Plunkett, H Kantarjian, M B Rios, M J Keating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8481661     DOI： 10.3109/10428199309149123

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Authors:  Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Harry P Erba; Arnaud Pigneux; Heinz-August Horst; Christian Recher; Virginia M Klimek; Jorge Cortes; Gail J Roboz; Olatoyosi Odenike; Xavier Thomas; Violaine Havelange; Johan Maertens; Hans-Günter Derigs; Michael Heuser; Lloyd Damon; Bayard L Powell; Gianluca Gaidano; Angelo-Michele Carella; Andrew Wei; Donna Hogge; Adam R Craig; Judith A Fox; Renee Ward; Jennifer A Smith; Gary Acton; Cyrus Mehta; Robert K Stuart; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2015-07-30       Impact factor: 41.316

2.  Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.

Authors:  Haifa Kathrin Al-Ali; Dietger Niederwieser; Thomas Heinicke; Rainer Krahl; Christoph Kahl; Michael Cross; Sebastian Scholl; Hans-Heinrich Wolf; Detlev Hähling; Ute Hegenbart; Norma Peter; Antje Schulze; Axel Florschütz; Volker Schmidt; Kolja Reifenrath; Niklas Zojer; Christian Junghanss; Herbert G Sayer; Georg Maschmeyer; Christian Späth; Andreas Hochhaus; Thomas Fischer
Journal:  Ann Hematol       Date:  2021-07-07       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.